← Back to Clinical Trials
Recruiting NCT07659535

NCT07659535 Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07659535
Status Recruiting
Phase
Sponsor Region Skane
Condition Type 2 Diabetes
Study Type INTERVENTIONAL
Enrollment 40,000 participants
Start Date 2026-06-15
Primary Completion 2029-12-31

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Lifestyle tool

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40,000 participants in total. It began in 2026-06-15 with a primary completion date of 2029-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall aim of the study is to investigate the incidence of type 2 diabetes in individuals who have access to a digital intervention tool as compared with randomized controls during three years. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.

Eligibility Criteria

Inclusion criteria * Informed consent * Age above 35 years * Access to Internet and mobile or computer device Exclusion criteria * diabetes mellitus * conditions or treatments that in the judgement of the Investigator could affect the study evaluation * connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected. * living outside of Sweden * inability to read and write in Swedish

Contact & Investigator

Central Contact

Birgitta Abrahamsson, MSc

✉ birgitta.x.abrahamsson@skane.se

📞 0705316704

Principal Investigator

Anders Rosengren, MD PhD

PRINCIPAL INVESTIGATOR

Göteborg University

Frequently Asked Questions

Who can join the NCT07659535 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07659535 currently recruiting?

Yes, NCT07659535 is actively recruiting participants. Contact the research team at birgitta.x.abrahamsson@skane.se for enrollment information.

Where is the NCT07659535 trial being conducted?

This trial is being conducted at Malmö, Sweden.

Who is sponsoring the NCT07659535 clinical trial?

NCT07659535 is sponsored by Region Skane. The principal investigator is Anders Rosengren, MD PhD at Göteborg University. The trial plans to enroll 40,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology